Back to discover

Protein / target

Basigin

Encoded byBSGP35613Homo sapiensSwiss-Prot
UniProt: P35613Ensembl: ENSG00000172270HGNC: HGNC:1116NCBI Gene: 682
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Cell-cell adhesion mediator

Strongest disease association

Metabolism, Inborn Errors

Via encoding gene BSG · Pathway evidence · score 0.37

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

2 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Essential for normal retinal maturation and development.

View complete UniProt function annotation

Essential for normal retinal maturation and development (By similarity). Acts as a retinal cell surface receptor for NXNL1 and plays an important role in NXNL1-mediated survival of retinal cone photoreceptors (PubMed:25957687). In association with glucose transporter SLC16A1/GLUT1 and NXNL1, promotes retinal cone survival by enhancing aerobic glycolysis and accelerating the entry of glucose into photoreceptors (PubMed:25957687). May act as a potent stimulator of IL6 secretion in multiple cell lines that include monocytes (PubMed:21620857)

Subcellular location

MelanosomeCell membranePhotoreceptor inner segmentCell projection, cilium, photoreceptor outer segmentEndosomeEndoplasmic reticulum membraneBasolateral cell membrane
Domains and Gene Ontology detail (46)

Domains & features

Ig-likeIg-like C2-typeIg-like V-type

Gene Ontology

  • Cacrosomal membrane
  • Caxon
  • Cbasolateral plasma membrane
  • Cendoplasmic reticulum membrane
  • Cendosome
  • Cextracellular exosome
  • Cfocal adhesion
  • CGolgi membrane
  • Cmelanosome
  • Cmembrane
  • Cmitochondrion
  • Cphotoreceptor inner segment

385 aa · 42 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOCell adhesionGO
View supporting evidence

Cell migration

  • ·neutrophil chemotaxis
  • ·positive regulation of endothelial cell migration

Cell adhesion

  • ·cell-cell adhesion mediator activity
  • ·homophilic cell-cell adhesion

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene BSG

Gene-level evidence surfaced through the gene BSGthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Graft vs Host Disease
0.29Limited support

Clinical evidence dominant · Open Targets 0.23

Metabolism, Inborn Errors
0.24Preliminary

Pathway evidence dominant · Open Targets 0.37 · no direct causal or clinical evidence

Neurodegenerative Diseases
0.22Preliminary

Pathway evidence dominant · Open Targets 0.28 · no direct causal or clinical evidence

Neoplasms
0.15Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Carcinoma, Hepatocellular
0.15Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

View evidence synthesis (5)
Graft vs Host DiseaseLimited support
0.29
agreement 0.13–0.44
Clinical98%Literature2%

Open Targets aggregate 0.23 · 2 independent evidence families

Metabolism, Inborn ErrorsPreliminary
0.24
agreement 0.01–0.47
Pathway100%

Open Targets aggregate 0.37 · 1 independent evidence family · no direct causal or clinical evidence

Neurodegenerative DiseasesPreliminary
0.22
agreement 0.04–0.40
Pathway77%Literature23%

Open Targets aggregate 0.28 · 2 independent evidence families · no direct causal or clinical evidence

NeoplasmsPreliminary
0.15
agreement 0.00–0.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

Carcinoma, HepatocellularPreliminary
0.15
agreement 0.00–0.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Metabolism, Inborn Errors0.37
Neurodegenerative Diseases0.28
Graft vs Host Disease0.23
Neoplasms0.12
Carcinoma, Hepatocellular0.12
Breast Neoplasms0.12
Arthritis, Rheumatoid0.11

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
GAVILIMOMABPhase 2 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Strong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (8)
SM · Structure with LigandSM · High-Quality PocketAB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.969 cites

Wang K · Signal transduction and targeted therapy · 2020

The monocarboxylate transporter family--role and regulation.558 cites

Halestrap AP · IUBMB life · 2012

Recent

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.

Wang K · Signal transduction and targeted therapy · 2020

The monocarboxylate transporter family--role and regulation.

Halestrap AP · IUBMB life · 2012

Europe PMC papers linked directly to this protein.